ClinicalTrials.gg
CompletedNCT04569032Updated Aug 13, 2026Results posted

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

A Phase 2 interventional study of brentuximab vedotin and cyclophosphamide in Peripheral T-cell Lymphoma, sponsored by Seagen, a wholly owned subsidiary of Pfizer. Completed at 63 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Seagen, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing Brentuximab Vedotin in Lymphoma, T-Cell, Peripheral — 3 open to participants now, 3 under way, 1 of them phase 3. Brentuximab Vedotin · Lymphoma, T-Cell, Peripheral.

Enrollment
3rd of 11
82 · median 33
Started
2020
the only one that year
Phase 2
6 of 11
1 open now
Registered
8th of 11
by date
Lead sponsor
1 of 11
Seagen, a wholly owned subsidiary of Pfizer

Among the 11 studies testing Brentuximab Vedotin in Lymphoma, T-Cell, Peripheral, this one is the 3rd largest by enrollment, is the only one that started in 2020, is one of 6 in phase 2, and was the 8th registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

3 of the 11 studies testing Brentuximab Vedotin in Lymphoma, T-Cell, Peripheral are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Brentuximab Vedotin in Lymphoma, T-Cell, Peripheral, or all of them as a file.
02

Study summary

This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out what side effects occur when brentuximab vedotin and CHP are used together. A side effect is anything the drugs do besides treating cancer. CHP is a type of chemotherapy that uses three drugs (cyclophosphamide, doxorubicin, and prednisone). CHP is approved by the FDA to treat certain types of PTCL.

03

Conditions studied

  • Peripheral T-cell Lymphoma

Keywords

  • CD30-positive
  • CD30-negative
  • Seattle Genetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed PTCL, excluding systemic anaplastic large cell lymphoma (sALCL), per the Revised European-American Lymphoma World Health Organization (WHO) 2016 classification
  • The following non-sALCL PTCL subtypes are eligible:

    • PTCL - not otherwise specified (PTCL-NOS)
    • Angioimmunoblastic T-cell lymphoma (AITL)
    • Adult T-cell leukemia/lymphoma (ATLL; acute and lymphoma types only, must be positive for human T cell leukemia virus 1)
    • Enteropathy-associated T-cell lymphoma (EATL)
    • Hepatosplenic T-cell lymphoma
    • Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITCL)
    • Indolent T-cell lymphoproliferative disorder (T-LPD) of the gastrointestinal (GI) tract
    • Follicular T-cell lymphoma
    • Nodal peripheral T-cell lymphoma with T-follicular helper (TFH) phenotype
  • CD30 expression \<10% by local assessment in tumor containing lymph node or other extranodal soft tissue
  • Fluorodeoxyglucose (FDG)-avid disease by PET and of at least 1.5 cm by CT, as assessed by the site radiologist
  • An (ECOG) performance status less than or equal to 2

Exclusion criteria

Exclusion Criteria

  • Current diagnosis of any of the following:

    • sALCL
    • Primary cutaneous T-cell lymphoproliferative disorders and lymphomas
    • Mycosis fungoides (MF), including transformed MF
  • History of another primary invasive cancer, hematologic , or myelodysplastic syndrome that has not been in remission for at least 3 years. Exceptions are malignancies with a negligible risk of or death (e.g., 5-year OS ≥90%), such as carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.
  • History of progressive multifocal leukoencephalopathy (PML).
  • Cerebral/meningeal disease related to the underlying malignancy.
  • Prior treatment with brentuximab vedotin or doxorubicin.
  • Baseline peripheral neuropathy Grade 2 or higher (per the , Version 4.03) or subjects with the demyelinating form of Charcot-Marie-Tooth syndrome.
  • less than 45% or symptomatic cardiac disease (including symptomatic ventricular dysfunction, symptomatic coronary artery disease, and symptomatic arrhythmias), or myocardial infarction within the past 6 months, or previous treatment with complete cumulative dose of >300 mg/m2 of doxorubicin.
  • Any uncontrolled Grade 3 or higher (per the National Cancer Institute's Common Terminology Criteria for Adverse Events, NCI CTCAE Version 4.03) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study drug. Routine antimicrobial prophylaxis is permitted.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    CD30-negative Cohort

    Participants with CD30 expression level \< 1%

    Drug: brentuximab vedotin · Drug: cyclophosphamide · Drug: doxorubicin · Drug: prednisone

  • Experimental
    CD30-positive Cohort

    Participants with CD30 expression level ≥1% to \< 10%

    Drug: brentuximab vedotin · Drug: cyclophosphamide · Drug: doxorubicin · Drug: prednisone

Interventions

  • 1.8 mg/kg administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle

    Also known as: ADCETRIS

  • 750 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle

  • 50 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle

  • 100 mg daily administered orally on Days 1-5 of each cycle

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) by Revised Response Criteria for Malignant Lymphoma Criteria (Cheson 2007) by Central CD30 Assessment

    ORR was defined as the percentage of participants with complete response (CR) or partial response (PR) following the completion of study treatment (at end of treatment \[EOT\]). CR and PR per Cheson 2007: CR was defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy and PR was defined as at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses.

    Time frame: At EOT or the first assessment after the last dose of study treatment (prior to long term follow-up or initiation of subsequent anti-cancer therapies); up to 41.91 months

Secondary outcomes

  1. Complete Response (CR) Rate Per BICR (Cheson 2007) by Central CD30 Assessment

    CR rate was defined as the percentage of participants with CR following the completion of study treatment (at EOT). CR as per Cheson 2007: CR was defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.

    Time frame: At EOT or the first assessment after the last dose of study treatment (prior to long term follow-up or initiation of subsequent anti-cancer therapies); up to 41.91 months

  2. Progression Free Survival (PFS) Per BICR (Cheson 2007) by Central CD30 Assessment

    PFS was defined as the time from start of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever came first. Kaplan-Meier method was used for analysis. PFS data was censored on the date of the last radiological assessment of measured lesions documenting absence of PD for participants without objective tumor progression and were still on study at the time of an analysis, were given antitumor treatment other than the study treatment or stem cell transplant (included donor lymphocyte infusion) or were removed from study prior to documentation of objective tumor progression. Participants who lacked an evaluation of tumor response after their first dose had their event time censored at 1 day.

    Time frame: From the first dose of study treatment to first documentation of objective tumor progression or death due to any cause or censoring, whichever came first (approximately 61.7 months)

  3. Overall Survival (OS) by Central CD30 Assessment

    OS was defined as the time from first dose to death due to any cause. Participant not known to have died by the end of study follow-up, observation of OS was censored on the date the participants were last known to be alive (i.e., date of last contact). Participants who lacked data beyond the day of first dose had their survival time censored on the date of first dose (i.e., OS duration of 1 day). Kaplan-Meier method was used for analysis.

    Time frame: From the first dose of study treatment until death or censoring date, whichever came first (approximately 61.7 months)

  4. Duration of Response (DOR) Per BICR (Cheson 2007) by Central CD30 Assessment

    DOR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression (per Cheson 2007) or death, whichever came first. Participants without progression or death were censored. DOR was only calculated for the subset of participants achieving a CR or PR. CR and PR per Cheson 2007: CR was defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy and PR was defined as at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses. Kaplan-Meier method was used for analysis.

    Time frame: From the first documented CR or PR until the first documentation of tumor progression, death or censoring date, whichever came first (up to 61.7 months)

  5. ORR Per BICR by Modified Lugano Criteria (Cheson 2014) by Central CD30 Assessment

    ORR was defined as the percentage of participants with CR or PR following the completion of study treatment (at EOT) according to the modified Lugano criteria (Cheson 2014). Complete response was defined as complete disappearance of radiologic evidence of disease and PR was defined as at least a 50% decrease in SPD of up to six of the largest dominant nodes or nodal masses.

    Time frame: At EOT or the first assessment after the last dose of study treatment (prior to long term follow-up or initiation of subsequent anti-cancer therapies); up to 41.91 months

  6. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Related Adverse Events by Local CD30 Assessment

    An adverse event was any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. An adverse event was classified as a serious adverse event (SAE) if it met one of the following criteria: fatal, life threatening, hospitalization, disabling/incapacitating, congenital anomaly or birth defect or any medically significant event. TEAEs were events if they were newly occurring or worsen following study treatment. TESAE is any SAE that met treatment emergent definition. Treatment related AEs were which had evidence to suggest a causal relationship between the drugs and the adverse event, such as: an event that was uncommon and known to be strongly associated with drug exposure, an event that was not commonly associated with drug exposure but was otherwise uncommon in the population exposed to the drug. AEs included both SAEs and all non-SAEs.

    Time frame: From first dose of the study treatment (Day 1) up to 30-37 days after the last dose of study treatment (approximately up to 6.6 months)

  7. Number of Participants With Treatment Emergent Laboratory Abnormalities as Per Worst Post Baseline Grading, by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 by Local CD30 Assessment

    Any Abnormal laboratory tests(Decreased values of hemoglobin,leukocytes,lymphocytes,neutrophils, platelets, calcium corrected for albumin,glomerular filtration rate estimated, glucose, phosphate, potassium,albumin,sodium and increased values of calcium corrected for albumin,creatinine, potassium, glucose, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, total Bilirubin, urate) that worsen from baseline were considered clinically significant by investigator.Abnormal test were recorded as AE if associated with accompanying symptoms,required additional diagnostic testing or medical/surgical intervention,study dosing change,study discontinuation,significant additional concomitant drug treatment,other therapy.As perNCI CTCAE grade(G)1:mild(asymptomatic or mild symptoms,clinical,diagnostic observations,no intervention),G2:moderate(minimal, local,noninvasive intervention),G3:severe,medically significant,G4:life-threatening,urgent intervention,G5:death related to AE

    Time frame: From first dose of the study treatment (Day 1) up to 30-37 days after the last dose of study treatment (approximately up to 6.6 months)

07

Results

Posted May 15, 2025

Participant flow

Participants who had newly diagnosed non-systemic anaplastic large cell lymphoma (sALCL) peripheral T-cell lymphoma (PTCL) with \< 10% CD30 expression, were enrolled to receive A+CHP treatment (brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone). Enrollment was based on CD30 expression per local laboratory assessment. Analysis of efficacy outcome measures was based on CD30 expression per central laboratory assessment.

Participant flow — Overall Study
MilestoneCD30 <1% [Local Laboratory Assessment]CD30 1% to <10% [Local Laboratory Assessment]
Started3448
Completed00
Not completed3448
Withdrew: Death1013
Withdrew: Withdrawal by subject20
Withdrew: Lost to follow-up01
Withdrew: In long term follow up2234

Outcome measures

PrimaryObjective Response Rate (ORR) Per Blinded Independent Central Review (BICR) by Revised Response Criteria for Malignant Lymphoma Criteria (Cheson 2007) by Central CD30 Assessment

ORR was defined as the percentage of participants with complete response (CR) or partial response (PR) following the completion of study treatment (at end of treatment \[EOT\]). CR and PR per Cheson 2007: CR was defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy and PR was defined as at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses.

Time frame:
At EOT or the first assessment after the last dose of study treatment (prior to long term follow-up or initiation of subsequent anti-cancer therapies); up to 41.91 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) by Revised Response Criteria for Malignant Lymphoma Criteria (Cheson 2007) by Central CD30 Assessment
Percentage of participantsCD30 <1% [Central Laboratory Assessment]CD30 1% to <10% [Central Laboratory Assessment]
Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) by Revised Response Criteria for Malignant Lymphoma Criteria (Cheson 2007) by Central CD30 Assessment61 (38.5 to 80.3)81 (62.5 to 92.5)
SecondaryComplete Response (CR) Rate Per BICR (Cheson 2007) by Central CD30 Assessment

CR rate was defined as the percentage of participants with CR following the completion of study treatment (at EOT). CR as per Cheson 2007: CR was defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.

Time frame:
At EOT or the first assessment after the last dose of study treatment (prior to long term follow-up or initiation of subsequent anti-cancer therapies); up to 41.91 months
Reported as:
Number · Percentage of participants
Complete Response (CR) Rate Per BICR (Cheson 2007) by Central CD30 Assessment
Percentage of participantsCD30 <1% [Central Laboratory Assessment]CD30 1% to <10% [Central Laboratory Assessment]
Complete Response (CR) Rate Per BICR (Cheson 2007) by Central CD30 Assessment52 (30.6 to 73.2)71 (52.0 to 85.8)
SecondaryProgression Free Survival (PFS) Per BICR (Cheson 2007) by Central CD30 Assessment

PFS was defined as the time from start of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever came first. Kaplan-Meier method was used for analysis. PFS data was censored on the date of the last radiological assessment of measured lesions documenting absence of PD for participants without objective tumor progression and were still on study at the time of an analysis, were given antitumor treatment other than the study treatment or stem cell transplant (included donor lymphocyte infusion) or were removed from study prior to documentation of objective tumor progression. Participants who lacked an evaluation of tumor response after their first dose had their event time censored at 1 day.

Time frame:
From the first dose of study treatment to first documentation of objective tumor progression or death due to any cause or censoring, whichever came first (approximately 61.7 months)

Results for this outcome have not been posted.

SecondaryOverall Survival (OS) by Central CD30 Assessment

OS was defined as the time from first dose to death due to any cause. Participant not known to have died by the end of study follow-up, observation of OS was censored on the date the participants were last known to be alive (i.e., date of last contact). Participants who lacked data beyond the day of first dose had their survival time censored on the date of first dose (i.e., OS duration of 1 day). Kaplan-Meier method was used for analysis.

Time frame:
From the first dose of study treatment until death or censoring date, whichever came first (approximately 61.7 months)

Results for this outcome have not been posted.

SecondaryDuration of Response (DOR) Per BICR (Cheson 2007) by Central CD30 Assessment

DOR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression (per Cheson 2007) or death, whichever came first. Participants without progression or death were censored. DOR was only calculated for the subset of participants achieving a CR or PR. CR and PR per Cheson 2007: CR was defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy and PR was defined as at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses. Kaplan-Meier method was used for analysis.

Time frame:
From the first documented CR or PR until the first documentation of tumor progression, death or censoring date, whichever came first (up to 61.7 months)

Results for this outcome have not been posted.

SecondaryORR Per BICR by Modified Lugano Criteria (Cheson 2014) by Central CD30 Assessment

ORR was defined as the percentage of participants with CR or PR following the completion of study treatment (at EOT) according to the modified Lugano criteria (Cheson 2014). Complete response was defined as complete disappearance of radiologic evidence of disease and PR was defined as at least a 50% decrease in SPD of up to six of the largest dominant nodes or nodal masses.

Time frame:
At EOT or the first assessment after the last dose of study treatment (prior to long term follow-up or initiation of subsequent anti-cancer therapies); up to 41.91 months
Reported as:
Number · Percentage of participants
ORR Per BICR by Modified Lugano Criteria (Cheson 2014) by Central CD30 Assessment
Percentage of participantsCD30 <1% [Central Laboratory Assessment]CD30 1% to <10% [Central Laboratory Assessment]
ORR Per BICR by Modified Lugano Criteria (Cheson 2014) by Central CD30 Assessment57 (34.5 to 76.8)77 (58.9 to 90.4)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Related Adverse Events by Local CD30 Assessment

An adverse event was any untoward medical occurrence in a participant or clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with this treatment. An adverse event was classified as a serious adverse event (SAE) if it met one of the following criteria: fatal, life threatening, hospitalization, disabling/incapacitating, congenital anomaly or birth defect or any medically significant event. TEAEs were events if they were newly occurring or worsen following study treatment. TESAE is any SAE that met treatment emergent definition. Treatment related AEs were which had evidence to suggest a causal relationship between the drugs and the adverse event, such as: an event that was uncommon and known to be strongly associated with drug exposure, an event that was not commonly associated with drug exposure but was otherwise uncommon in the population exposed to the drug. AEs included both SAEs and all non-SAEs.

Time frame:
From first dose of the study treatment (Day 1) up to 30-37 days after the last dose of study treatment (approximately up to 6.6 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Treatment Related Adverse Events by Local CD30 Assessment
ParticipantsCD30 <1% [Local Laboratory Assessment]CD30 1% to <10% [Local Laboratory Assessment]
TEAEs3246
TESAEs1516
Treatment related TEAEs2540
SecondaryNumber of Participants With Treatment Emergent Laboratory Abnormalities as Per Worst Post Baseline Grading, by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 by Local CD30 Assessment

Any Abnormal laboratory tests(Decreased values of hemoglobin,leukocytes,lymphocytes,neutrophils, platelets, calcium corrected for albumin,glomerular filtration rate estimated, glucose, phosphate, potassium,albumin,sodium and increased values of calcium corrected for albumin,creatinine, potassium, glucose, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, total Bilirubin, urate) that worsen from baseline were considered clinically significant by investigator.Abnormal test were recorded as AE if associated with accompanying symptoms,required additional diagnostic testing or medical/surgical intervention,study dosing change,study discontinuation,significant additional concomitant drug treatment,other therapy.As perNCI CTCAE grade(G)1:mild(asymptomatic or mild symptoms,clinical,diagnostic observations,no intervention),G2:moderate(minimal, local,noninvasive intervention),G3:severe,medically significant,G4:life-threatening,urgent intervention,G5:death related to AE

Time frame:
From first dose of the study treatment (Day 1) up to 30-37 days after the last dose of study treatment (approximately up to 6.6 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Laboratory Abnormalities as Per Worst Post Baseline Grading, by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 by Local CD30 Assessment
ParticipantsCD30 <1% [Local Laboratory Assessment]CD30 1% to <10% [Local Laboratory Assessment]
Hemoglobin decreased: Grade 1+21934
Hemoglobin decreased: Grade 331
Leukocytes decreased: Grade 1+21323
Leukocytes decreased: Grade 345
Leukocytes decreased: Grade 401
Lymphocytes decreased: Grade 1+21015
Lymphocytes decreased: Grade 31521
Lymphocytes decreased: Grade 414
Neutrophils decreased: Grade 1+2312
Neutrophils decreased: Grade 343
Neutrophils decreased: Grade 413
Platelets decreased: Grade 1+2610
Platelets decreased: Grade 401
Calcium Corrected for Albumin increased: Grade 1+231
Creatinine increased: Grade 1+21930
Glomerular Filtration Rate, Estimated decreased: Grade 1+224
Glucose decreased: Grade 1+215
Glucose increased: Grade 1+21521
Glucose increased: Grade 330
Glucose increased: Grade 401
Phosphate decreased: Grade 1+211
Phosphate decreased: Grade 304
Potassium decreased: Grade 1+225
Potassium decreased: Grade 311
Potassium decreased: Grade 401
Alanine Aminotransferase increased: Grade 1+2617
Albumin decreased: Grade 1+238
Alkaline Phosphatase increased: Grade 1+2211
Alkaline Phosphatase increased: Grade 320
Aspartate Aminotransferase increased: Grade 1+2815
Aspartate Aminotransferase increased: Grade 301
Calcium Corrected for Albumin decreased: Grade 1+222
Potassium increased: Grade 1+224
Potassium increased: Grade 310
Sodium decreased: Grade 1+286
Sodium decreased: Grade 313
Sodium increased: Grade 1+202
Total Bilirubin increased: Grade 1+211
Urate increased: Grade 346
Urate increased: Grade 420

Adverse events

Collected over Adverse events: From first dose of the study treatment (Day 1) maximum up to 30-37 days after the last dose of study treatment (approximately up to 6.6 months). All-cause mortality: throughout the study (up to 41 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CD30 <1% [Local Laboratory Assessment]11/34 (32.4%)15/34 (44.1%)31/34 (91.2%)
CD30 1% to <10% [Local Laboratory Assessment]13/48 (27.1%)16/48 (33.3%)43/48 (89.6%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventCD30 <1% [Local Laboratory Assessment]CD30 1% to <10% [Local Laboratory Assessment]
Febrile neutropeniaBlood and lymphatic system disorders6/349/48
PyrexiaGeneral disorders4/341/48
DiarrhoeaGastrointestinal disorders2/341/48
FatigueGeneral disorders2/340/48
AnaemiaBlood and lymphatic system disorders0/342/48
HypoxiaRespiratory, thoracic and mediastinal disorders0/342/48
PancytopeniaBlood and lymphatic system disorders1/340/48
DysphagiaGastrointestinal disorders1/340/48
EnteritisGastrointestinal disorders1/340/48
Chest painGeneral disorders1/340/48
Most frequent other events
Showing 10 of 47
Most frequent other events
EventCD30 <1% [Local Laboratory Assessment]CD30 1% to <10% [Local Laboratory Assessment]
DiarrhoeaGastrointestinal disorders6/3419/48
Peripheral sensory neuropathyNervous system disorders11/3416/48
AnaemiaBlood and lymphatic system disorders7/3415/48
NauseaGastrointestinal disorders8/3414/48
NeutropeniaBlood and lymphatic system disorders4/3412/48
PyrexiaGeneral disorders2/348/48
AstheniaGeneral disorders5/343/48
Oedema peripheralGeneral disorders5/346/48
ConstipationGastrointestinal disorders3/347/48
VomitingGastrointestinal disorders4/347/48

Baseline characteristics

Age, Continuous
Age, Continuous(Years)CD30 <1% [Local Laboratory Assessment]CD30 1% to <10% [Local Laboratory Assessment]Total
Mean60.2 ± 11.361.0 ± 11.060.7 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)CD30 <1% [Local Laboratory Assessment]CD30 1% to <10% [Local Laboratory Assessment]Total
Female102636
Male242246
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CD30 <1% [Local Laboratory Assessment]CD30 1% to <10% [Local Laboratory Assessment]Total
Hispanic or Latino91019
Not Hispanic or Latino223456
Unknown or Not Reported347
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CD30 <1% [Local Laboratory Assessment]CD30 1% to <10% [Local Laboratory Assessment]Total
American Indian or Alaska Native000
Asian246
Native Hawaiian or Other Pacific Islander000
Black or African American224
White263763
More than one race000
Unknown or Not Reported459
08

Study locations

63 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • Stanford Hospital and Clinics, Investigational Drug Services
    Stanford, California 94305, United States
  • Rocky Mountain Cancer centers, LLP
    Aurora, Colorado 80012, United States
  • Rocky Mountain Cancer centers, LLP
    Boulder, Colorado 80303, United States
  • Rocky Mountain Cancer centers, LLP
    Colorado Springs, Colorado 80907, United States
  • Rocky Mountain Cancer centers, LLP
    Denver, Colorado 80218, United States
  • Rocky Mountain Cancer centers, LLP
    Denver, Colorado 80220, United States
  • Rocky Mountain Cancer centers, LLP
    Lakewood, Colorado 80228, United States
  • Rocky Mountain Cancer centers, LLP
    Littleton, Colorado 80120, United States
  • Rocky Mountain Cancer centers, LLP
    Lone Tree, Colorado 80124, United States
  • Rocky Mountain Cancer centers, LLP
    Longmont, Colorado 80504, United States
  • Rocky Mountain Cancer centers, LLP
    Pueblo, Colorado 81003, United States
  • Rocky Mountain Cancer centers, LLP
    Thornton, Colorado 80260, United States
  • Tulane Cancer Center
    New Orleans, Louisiana 70112, United States
  • Tulane Medical Center
    New Orleans, Louisiana 70112, United States
  • Memorial Sloan Kettering Cancer Center David H. Koch Center for Cancer Care
    New York, New York 10021, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Cleveland Clinic taussig Cancer Center Investigational Pharmacy
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic, The
    Cleveland, Ohio 44195, United States
  • Texas Oncology - Central/South Texas
    Austin, Texas 78705, United States
  • Texas Oncology - Central South (Balcones Dr)
    Austin, Texas 78731, United States
  • Texas Oncology - Central South (James Casey)
    Austin, Texas 78745, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • US Oncology Investigational Products Center (IPC)
    Irving, Texas 75063, United States
  • US Oncology Investigational Products Center(IPC)
    Irving, Texas 75063, United States
  • US Oncology lnvestigational Products Center (IPC)
    Irving, Texas 75063, United States
  • Texas Oncology-Northeast Texas
    Longview, Texas 75601, United States
  • Texas Oncology-Northeast Texas
    Palestine, Texas 75801, United States
  • Texas Oncology-Northeast Texas
    Paris, Texas 75460, United States
  • Texas Oncology-Northeast Texas
    Tyler, Texas 75702, United States
  • Virginia Oncology Associates
    Chesapeake, Virginia 23320, United States
  • Virginia Oncology Associates
    Hampton, Virginia 23666, United States
  • Virginia Oncology Associates
    Newport News, Virginia 23606, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • VCU Massey Cancer Center-Radiation Oncology
    Richmond, Virginia 23219, United States
  • VCU Medical Center -InPatient
    Richmond, Virginia 23219, United States
  • VCU Medical Center Critical Care Hospital
    Richmond, Virginia 23219, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23219, United States
  • VCU at Stony Point
    Richmond, Virginia 23235, United States
  • Massey Cancer Center Clinical & Translational Research Lab
    Richmond, Virginia 23298, United States
  • Virginia Oncology Associates
    Virginia Beach, Virginia 23456, United States
  • CHU Grenoble Alpes
    Tronche, Auvergne-Rhône-Alpes 38700, France
  • Hopital Emile Muller
    Mulhouse, 68070, France
  • Höpital Haut Levéque - CHU Bordeaux Service d'hématologie clinique et thérapie cellulaire
    Pessac, 33604, France
  • Azienda Ospedaliero Universitaria di Bologna - IRCCS
    Bologna, Emilia-Romagna 40138, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milan, Lombardy 20122, Italy
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, Lombardy 27100, Italy
  • IRCCS Ospedale Policlinico San Martino
    Genova, Other 16132, Italy
  • Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS Candiolo - Oncologia Medica
    Candiolo, Turin 10060, Italy
  • Azienda Ospedaliera Universitaria Integrata Verona Policlinico G.B. Rossi
    Verona, 37134, Italy
  • IEC Trials, Hospital La Milagrosa.
    Madrid, Other 28010, Spain
  • Hospital Universitario De La Paz
    Madrid, Other 28046, Spain
  • Cetir Centre Medic
    Barcelona, 08029, Spain
  • Hospital Duran I Reynals - Institut Catala d'Oncologia
    Barcelona, 08908, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Clinico Universitario de Salamanca
    Salamanca, 37007, Spain
  • Oxford University Hospitals
    Headington, Oxford OX3 7LE, United Kingdom
  • UCLH Hospitals
    London, NWI 2BG, United Kingdom
  • Hammersmith Hospital
    London, W12 0HS, United Kingdom
  • MACMILLIAN Cancer Centre
    London, WC1E 6AG, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in May 2024, 41 months.

Results were first posted in May 2025, 1 year after primary completion.

Of 64 phase 2 interventional studies under Lymphoma, T-Cell, Peripheral, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 96. This study's 41 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2020
First posted
Sep 29, 2020
StartActual
Nov 12, 2020
Primary completionActual
May 9, 2024
CompletionActual
Jan 12, 2026
Results first posted
May 15, 2025
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04569032
Responsible party
Sponsor
First posted
Sep 29, 2020
Start date
Nov 12, 2020
Primary completion
May 9, 2024
Completion
Jan 12, 2026
Results posted
May 15, 2025
Last update
Aug 13, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion